Deciphering pharmacokinetics and pharmacodynamics of fosfomycin

Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in health...

Full description

Saved in:
Bibliographic Details
Published inRevista española de quimioterapia Vol. 32 Suppl 1; no. Suppl 1; pp. 19 - 24
Main Authors Rodríguez-Gascón, A, Canut-Blasco, A
Format Journal Article
LanguageEnglish
Published Spain Sociedad Española de Quimioterapia 01.05.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L.
AbstractList Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa . As PK/PD targets, we selected %T >MIC > 70% for all pathogens, and AUC 24 /MIC > 24 and AUC 24 /MIC > 15 for net stasis of Enterobacterales and P. aeruginosa , respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T >MIC and AUC 24 /MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L.
Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L.Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L.
Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose clearance is subject to patient renal function. The volume of distribution approximates to the extracellular body water (about 0.3 L/Kg) in healthy volunteers, but it is increased in critically ill patients with bacterial infections. Fosfomycin presents a high ability to distribute into many tissues, including inflamed tissues and abscess fluids. Based on PK/PD analysis and Monte Carlo simulations, we have evaluated different fosfomycin dosing regimen to optimize the treatment of septic patients due to Enterobacterales and Pseudomonas aeruginosa. As PK/PD targets, we selected %T>MIC > 70% for all pathogens, and AUC24/MIC > 24 and AUC24/MIC > 15 for net stasis of Enterobacterales and P. aeruginosa, respectively. Pharmacokinetic parameters in critically ill patients were obtained from the literature. Several dosing regimens were studied in patients with normal renal function: fosfomycin 2-8 g given every 6-12 hours, infused over 30 minutes- 24 hours. At the susceptibility EUCAST breakpoint for Enterobacterales and Staphylococcus spp. (MIC ≤ 32 mg/L), fosfomycin 4 g/8h or higher infused over 30 minutes achieved a probability of target attainment (PTA) > 90%, based in both %T>MIC and AUC24/MIC. For MIC of 64 mg/L, fosfomycin 6 g/6h in 30-minute infusion and 8 g/ 8h in 30-minute and 6 hours infusions also achieved PTA values higher than 90%. No fosfomycin monotherapy regimen was able to achieve PK/PD targets related to antimicrobial efficacy for P. aeruginosa with MICs of 256-512 mg/L.
Author Canut-Blasco, A
Rodríguez-Gascón, A
Author_xml – sequence: 1
  givenname: A
  surname: Rodríguez-Gascón
  fullname: Rodríguez-Gascón, A
– sequence: 2
  givenname: A
  surname: Canut-Blasco
  fullname: Canut-Blasco, A
  email: andres.canutblasco@osakidetza.eus
  organization: Andrés Canut-Blasco. Microbiology Service, Edificio Consultas Externas, Hospital Universitario de Álava. c/Francisco Leandro de Viana, s/n. 01009. Vitoria-Gasteiz, Spain. andres.canutblasco@osakidetza.eus
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31131588$$D View this record in MEDLINE/PubMed
BookMark eNpVkMtOwzAQRS1URB_wC6hLNpE8fiT2BoTKU6rEBtaW49itIbFDnCD17wmiVGU1M3dG517NHE1CDPYEzUAKkUkOYnLUT9E8pXeMGWUSztCUAlDgQszQzZ01vt3azofNst3qrtEmfvhge2_SUofqIFa7oJsfMbqli8nFZmd8OEenTtfJXuzrAr093L-unrL1y-Pz6nadtSTP-6yUpCAmx9KVGLuSisKC1XgMAQxsoQWuCiOKklW5LLFkuRhHapnj3ADWhC7Q9S-3HcrGVsaGvtO1ajvf6G6novbq_yb4rdrEL5VzziGnI-BqD-ji52BTrxqfjK1rHWwckiKEEgABwMbTy2Ovg8nf1-g3MIds1Q
ContentType Journal Article
Copyright The Author 2019 2019
Copyright_xml – notice: The Author 2019 2019
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1988-9518
EndPage 24
ExternalDocumentID PMC6555163
31131588
Genre Journal Article
Review
GroupedDBID ---
123
2WC
ADBBV
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CGR
CUY
CVF
DIK
EBD
EBS
ECM
EIF
EJD
EML
F5P
FRP
GROUPED_DOAJ
GX1
HYE
NPM
OK1
RPM
W2D
7X8
5PM
EMOBN
M~E
SV3
ID FETCH-LOGICAL-p266t-b9272c609fb00fb387e1ea0315141e7a80d7c87b4d69b094687c83e4f55c10a23
ISSN 1988-9518
0214-3429
IngestDate Thu Aug 21 18:34:30 EDT 2025
Fri Jul 11 10:16:14 EDT 2025
Thu May 23 23:47:52 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue Suppl 1
Language English
License The article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p266t-b9272c609fb00fb387e1ea0315141e7a80d7c87b4d69b094687c83e4f55c10a23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC6555163
PMID 31131588
PQID 2232118114
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6555163
proquest_miscellaneous_2232118114
pubmed_primary_31131588
PublicationCentury 2000
PublicationDate 2019-May
20190501
PublicationDateYYYYMMDD 2019-05-01
PublicationDate_xml – month: 05
  year: 2019
  text: 2019-May
PublicationDecade 2010
PublicationPlace Spain
PublicationPlace_xml – name: Spain
PublicationTitle Revista española de quimioterapia
PublicationTitleAlternate Rev Esp Quimioter
PublicationYear 2019
Publisher Sociedad Española de Quimioterapia
Publisher_xml – name: Sociedad Española de Quimioterapia
SSID ssj0043491
Score 2.2614105
SecondaryResourceType review_article
Snippet Fosfomycin, a low molecular weight and hydrophilic drug with negligible protein binding, is eliminated almost exclusively by glomerular filtration, whose...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 19
SubjectTerms Animals
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Current Key Topics in Fosfomycin
Fosfomycin - pharmacokinetics
Fosfomycin - pharmacology
Fosfomycin - therapeutic use
Humans
Title Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
URI https://www.ncbi.nlm.nih.gov/pubmed/31131588
https://www.proquest.com/docview/2232118114
https://pubmed.ncbi.nlm.nih.gov/PMC6555163
Volume 32 Suppl 1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELaaHKpcqvS9fcmVqlyIqzU2Bk5V82ijSqm21UbKbWUbk6J2gXThsPn1HWNYWJpDmwva9S4I-Rt9nvH4m0HonbarICw7hAH9E-5LQWBZYETzMJLGFpRqmvadfxVnF_zLZXDZHx1q1CWVeq9vbtWV3AVVGANcrUr2P5DdPBQG4DPgC1dAGK7_hPGJ0VnZCPiuvLKtQf0T3MZN6eVuMHF955tjG2kBjupyrduS211xbqsyr6RngGFs8vyIQszrJca7rrNlVlidcpltKPx7kbgU-8lVbW7IZ7nSzU3MFST4ZfdK-uxGXlfkCLx0XXRHKF16fmvLwaqcguGWQ3OeNJGJdzp-pW9_vZJjMp9yawyOG41j2hjABPcuGlJxv9VZWykM-OEeHbBrS65unXbS6wHK5bKBmVHKaOB6BY5Kac_Oj0VgM4NsB-0wyrsI3C3cnHHXYLF72z10v3vYbfHH-BjtwC-Z76MHbUCBPzrreIjumfwROpg54NeHeN4L7FaH-ADP-lrl68fow8CE8NiEMJgQHpsQLlLcm9ATdPHpdH58RtqeGqQEV6wiKvZDX4tpnALfpopFoaFG2lYflFMTymiahDoKFU9ErCD0FxF8ZYanQaDpVPrsKdrNi9w8Rzg2KQTrqRAR1TyWXCaxURLi62molIjkBL3t5mwBnGUTUTI3Rb1aADf4VvBM-QQ9c3O4KF1xlUU34xMUbs3u5g-2Hvr2L3n2o6mL3mL74s53vkR7vbm_QrvV79q8Bp-zUm8aS_kDwDWI5w
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Deciphering+pharmacokinetics+and+pharmacodynamics+of+fosfomycin&rft.jtitle=Revista+espa%C3%B1ola+de+quimioterapia&rft.au=Rodr%C3%ADguez-Gasc%C3%B3n%2C+Alicia&rft.au=Canut-Blasco%2C+Andr%C3%A9s&rft.date=2019-05-01&rft.pub=Sociedad+Espa%C3%B1ola+de+Quimioterapia&rft.issn=0214-3429&rft.eissn=1988-9518&rft.volume=32&rft.issue=Suppl+1&rft.spage=19&rft.epage=24&rft_id=info%3Apmid%2F31131588&rft.externalDocID=PMC6555163
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1988-9518&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1988-9518&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1988-9518&client=summon